139 related articles for article (PubMed ID: 31401767)
1. Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.
Hasegawa D; Yoshimoto Y; Kimura S; Kumamoto T; Maeda N; Hara J; Kikuta A; Kada A; Kimura T; Iijima-Yamashita Y; Saito AM; Horibe K; Manabe A; Ogawa C
Int J Hematol; 2019 Nov; 110(5):627-634. PubMed ID: 31401767
[TBL] [Abstract][Full Text] [Related]
2. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
3. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Messinger Y; Gaynon P; Raetz E; Hutchinson R; Dubois S; Glade-Bender J; Sposto R; van der Giessen J; Eckroth E; Bostrom BC
Pediatr Blood Cancer; 2010 Aug; 55(2):254-9. PubMed ID: 20582937
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
Keino D; Ohyama R; Ashikaga T; Morimoto M; Yamashita A; Kondoh K; Kinoshita A
Rinsho Ketsueki; 2014 Mar; 55(3):327-33. PubMed ID: 24681936
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
Iguchi A; Cho Y; Sugiyama M; Terashita Y; Ariga T; Hosoya Y; Hirabayashi S; Manabe A; Hara K; Aiba T; Shiokawa T; Tada H; Sato N
Int J Hematol; 2017 Aug; 106(2):291-298. PubMed ID: 28401497
[TBL] [Abstract][Full Text] [Related]
7. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Nachmias B; Shaulov A; Gatt ME; Shapira M; Gural A
Acta Haematol; 2018; 140(4):209-214. PubMed ID: 30343286
[TBL] [Abstract][Full Text] [Related]
8. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
9. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
[TBL] [Abstract][Full Text] [Related]
10. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
[TBL] [Abstract][Full Text] [Related]
11. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
Kaspers GJL; Niewerth D; Wilhelm BAJ; Scholte-van Houtem P; Lopez-Yurda M; Berkhof J; Cloos J; de Haas V; Mathôt RA; Attarbaschi A; Baruchel A; de Bont ES; Fagioli F; Rössig C; Klingebiel T; De Moerloose B; Nelken B; Palumbo G; Reinhardt D; Rohrlich PS; Simon P; von Stackelberg A; Zwaan CM
Br J Haematol; 2018 May; 181(4):523-527. PubMed ID: 29676440
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia.
Miyagawa N; Goto H; Ogawa A; Kikuta A; Kosaka Y; Sekimizu M; Tomizawa D; Toyoda H; Hiramatsu H; Hara J; Mochizuki S; Nakayama H; Yoshimura K; Iijima-Yamashita Y; Sanada M; Ogawa C
Int J Hematol; 2023 Aug; 118(2):267-276. PubMed ID: 37127801
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
[TBL] [Abstract][Full Text] [Related]
14. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1).
Raetz EA; Teachey DT; Minard C; Liu X; Norris RE; Denic KZ; Reid J; Evensen NA; Gore L; Fox E; Loh ML; Weigel BJ; Carroll WL
Pediatr Blood Cancer; 2023 Nov; 70(11):e30609. PubMed ID: 37553297
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
18. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Burke MJ; Kostadinov R; Sposto R; Gore L; Kelley SM; Rabik C; Trepel JB; Lee MJ; Yuno A; Lee S; Bhojwani D; Jeha S; Chang BH; Sulis ML; Hermiston ML; Gaynon P; Huynh V; Verma A; Gardner R; Heym KM; Dennis RM; Ziegler DS; Laetsch TW; Oesterheld JE; Dubois SG; Pollard JA; Glade-Bender J; Cooper TM; Kaplan JA; Farooqi MS; Yoo B; Guest E; Wayne AS; Brown PA
Clin Cancer Res; 2020 May; 26(10):2297-2307. PubMed ID: 31969338
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
